Plasma Sphingolipids, Lung Function and COPD: the Cardiovascular Health Study

Overview

Journal ERJ Open Res

Specialty Pulmonary Medicine

Date 2023 Apr 6

PMID 37020834

Authors

Arya R Gharib

Paul N Jensen

Bruce M Psaty

Andrew N Hoofnagle

David Siscovick

Sina A Gharib

Colleen M Sitlani

Nona Sotoodehnia

Rozenn N Lemaitre

Affiliations

Soon will be listed here.

Abstract

Rationale: COPD is the third leading cause of death in the United States. Sphingolipids, structural membrane constituents that play a role in cellular stress and apoptosis signalling, may be involved in lung function.

Methods: In the Cardiovascular Health Study, a prospective cohort of older adults, we cross-sectionally examined the association of plasma levels of 17 sphingolipid species with lung function and COPD. Multivariable linear regression and logistic regression were used to evaluate associations of sphingolipid concentrations with forced expiratory volume in 1 s (FEV) and odds of COPD, respectively.

Results: Of the 17 sphingolipids evaluated, ceramide-18 (Cer-18) and sphingomyelin-18 (SM-18) were associated with lower FEV values (-0.061 L per two-fold higher Cer-18, p=0.001; -0.092 L per two-fold higher SM-18, p=0.002) after correction for multiple testing. Several other associations were significant at a 0.05 level, but did not reach statistical significance after correction for multiple testing. Specifically, Cer-18 and SM-18 were associated with higher odds of COPD (odds ratio per two-fold higher Cer-18 1.29, p=0.03 and SM-18 1.73, p=0.008). Additionally, Cer-16 and SM-16 were associated with lower FEV values, and Cer-14, SM-14 and SM-16 with a higher odds of COPD.

Conclusion: In this large cross-sectional study, specific ceramides and sphingomyelins were associated with reduced lung function in a population-based study. Future studies are needed to examine whether these biomarkers are associated with longitudinal change in FEV within individuals or with incident COPD.

References

Levy M, Khan E, Careaga M, Goldkorn T . Neutral sphingomyelinase 2 is activated by cigarette smoke to augment ceramide-induced apoptosis in lung cell death. Am J Physiol Lung Cell Mol Physiol. 2009; 297(1):L125-33. PMC: 2711801. DOI: 10.1152/ajplung.00031.2009. View

Turpin-Nolan S, Bruning J . The role of ceramides in metabolic disorders: when size and localization matters. Nat Rev Endocrinol. 2020; 16(4):224-233. DOI: 10.1038/s41574-020-0320-5. View

Chakinala R, Khatri A, Gupta K, Koike K, Epelbaum O . Sphingolipids in COPD. Eur Respir Rev. 2019; 28(154). PMC: 9488540. DOI: 10.1183/16000617.0047-2019. View

Bowler R, Jacobson S, Cruickshank C, Hughes G, Siska C, Ory D . Plasma sphingolipids associated with chronic obstructive pulmonary disease phenotypes. Am J Respir Crit Care Med. 2014; 191(3):275-84. PMC: 4351578. DOI: 10.1164/rccm.201410-1771OC. View

Petrache I, Kamocki K, Poirier C, Pewzner-Jung Y, Laviad E, Schweitzer K . Ceramide synthases expression and role of ceramide synthase-2 in the lung: insight from human lung cells and mouse models. PLoS One. 2013; 8(5):e62968. PMC: 3653891. DOI: 10.1371/journal.pone.0062968. View

Grosch S, Schiffmann S, Geisslinger G . Chain length-specific properties of ceramides. Prog Lipid Res. 2011; 51(1):50-62. DOI: 10.1016/j.plipres.2011.11.001. View

Pauwels R, Buist A, Calverley P, Jenkins C, Hurd S . Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am J Respir Crit Care Med. 2001; 163(5):1256-76. DOI: 10.1164/ajrccm.163.5.2101039. View

Zheng J, Wen F, Bai C, Wan H, Kang J, Chen P . Twice daily N-acetylcysteine 600 mg for exacerbations of chronic obstructive pulmonary disease (PANTHEON): a randomised, double-blind placebo-controlled trial. Lancet Respir Med. 2014; 2(3):187-94. DOI: 10.1016/S2213-2600(13)70286-8. View

Mannino D, Buist A . Global burden of COPD: risk factors, prevalence, and future trends. Lancet. 2007; 370(9589):765-73. DOI: 10.1016/S0140-6736(07)61380-4. View

10.

Yang Y, Uhlig S . The role of sphingolipids in respiratory disease. Ther Adv Respir Dis. 2011; 5(5):325-44. DOI: 10.1177/1753465811406772. View

11.

Ahmed F, Jiang X, Schwartz J, Hoffman E, Yeboah J, Shea S . Plasma sphingomyelin and longitudinal change in percent emphysema on CT. The MESA lung study. Biomarkers. 2014; 19(3):207-13. PMC: 4088962. DOI: 10.3109/1354750X.2014.896414. View

12.

Baumgartner T, Zurauskaite G, Steuer C, Bernasconi L, Huber A, Mueller B . Association of serum sphingomyelin profile with clinical outcomes in patients with lower respiratory tract infections: results of an observational, prospective 6-year follow-up study. Clin Chem Lab Med. 2018; 57(5):679-689. DOI: 10.1515/cclm-2018-0509. View

13.

Pinto S, Silva L, Futerman A, Prieto M . Effect of ceramide structure on membrane biophysical properties: the role of acyl chain length and unsaturation. Biochim Biophys Acta. 2011; 1808(11):2753-60. DOI: 10.1016/j.bbamem.2011.07.023. View

14.

Fried L, Borhani N, Enright P, Furberg C, Gardin J, Kronmal R . The Cardiovascular Health Study: design and rationale. Ann Epidemiol. 1991; 1(3):263-76. DOI: 10.1016/1047-2797(91)90005-w. View

15.

Filosto S, Castillo S, Danielson A, Franzi L, Khan E, Kenyon N . Neutral sphingomyelinase 2: a novel target in cigarette smoke-induced apoptosis and lung injury. Am J Respir Cell Mol Biol. 2010; 44(3):350-60. PMC: 3095936. DOI: 10.1165/rcmb.2009-0422OC. View

16.

Parveen F, Bender D, Law S, Mishra V, Chen C, Ke L . Role of Ceramidases in Sphingolipid Metabolism and Human Diseases. Cells. 2019; 8(12). PMC: 6952831. DOI: 10.3390/cells8121573. View

17.

Lemaitre R, Jensen P, Hoofnagle A, McKnight B, Fretts A, King I . Plasma Ceramides and Sphingomyelins in Relation to Heart Failure Risk. Circ Heart Fail. 2019; 12(7):e005708. PMC: 6629465. DOI: 10.1161/CIRCHEARTFAILURE.118.005708. View

18.

Mizumura K, Justice M, Schweitzer K, Krishnan S, Bronova I, Berdyshev E . Sphingolipid regulation of lung epithelial cell mitophagy and necroptosis during cigarette smoke exposure. FASEB J. 2017; 32(4):1880-1890. PMC: 5893175. DOI: 10.1096/fj.201700571R. View

19.

Petrache I, Natarajan V, Zhen L, Medler T, Richter A, Cho C . Ceramide upregulation causes pulmonary cell apoptosis and emphysema-like disease in mice. Nat Med. 2005; 11(5):491-8. PMC: 1352344. DOI: 10.1038/nm1238. View

20.

Meeusen J, Donato L, Bryant S, Baudhuin L, Berger P, Jaffe A . Plasma Ceramides. Arterioscler Thromb Vasc Biol. 2018; 38(8):1933-1939. DOI: 10.1161/ATVBAHA.118.311199. View